MYLK and urinary bladder carcinoma: In bladder cancer, circRNA-MYLK served as miR-29a sponge and then activated VEGFA/VEGFR2 and downstream Ras/ERK signaling pathway, thereby promoting the proliferation, metastasis and epithelial-mesenchymal transition of bladder cancer cells [34].